

# NEW CLINICAL TRIAL OPEN FOR INCLUSION

## PROTOCOL TITLE

Pembrolizumab and Radiotherapy for Oligometastatic squamous cell carcinoma of the head and Neck: a randomized phase III study

## ALIAS

PROLoNg studie

## CTO NUMBER

CTOR20125EOR

## SPONSOR

EORTC

## KEY INCLUSION CRITERIA

Histologically confirmed HNSCC, 1-5 oligometastases (histologically or radiologically confirmed oligometastatic disease) and PD-L1 CPS  $\geq 1$ .

All 1-5 metastases must be amenable to SABR and eligible for treatment with pembrolizumab. Measurable disease and ECOG performance status of 0 or 1.

Staging not older than 12 weeks

## KEY EXCLUSION CRITERIA

Nasopharynx, sino-nasal, and salivary gland cancers are excluded.


In-field progression in < 6 months after curative intended locoregional irradiation.

Lesions  $> 6$  cm\*, non resected brain metastases  $> 4$  cm or brain metastases only.

Any previous radiotherapy to any of the 1-5 metastases that would be subject to SABR.

\* bone lesions  $> 6$  cm safely amenable to SABR according to the physician, are allowed

## DESIGN



<sup>1</sup>SABR: 3 fraction regimen (1 fraction every second day) or 5 fraction regimen (daily), according to the section 6.7.6 of the protocol.

## PRINCIPAL INVESTIGATOR

Dr Jean-François Daisne  
[jeanfrancois.daisne@zas.be](mailto:jeanfrancois.daisne@zas.be)

## STUDY COORDINATOR(S)

Kathleen Traets  
[kathleen.traets@zas.be](mailto:kathleen.traets@zas.be)

Jo Horemans  
[jo.horemans@zas.be](mailto:jo.horemans@zas.be)